You are currently browsing the archives for 10 August 2018.
Displaying 1 - 2 of 2 entries.

334 shares of its common stock at a price per share of $0.

Chardan Capital Markets, LLC acted as the exceptional placement agent for the transaction. Roth Capital Partners served as the economic advisor to CEL-SCI in the purchase. All the securities were provided pursuant to an effective shelf registration statement. A shelf registration statement associated with the shares of common share and warrants issued in the offering offers been filed with, and declared effective by, the Securities and Exchange Commission . A prospectus supplement relating to the offering provides been filed with the SEC. Electronic copies of the prospectus product and accompanying prospectus may be obtained at the SEC’s website at.. CEL-SCI closes previously announced registered direct offering CEL-SCI Corporation declared today that it has shut its previously announced authorized direct offering for the sale of 13,333,334 shares of its common stock at a price per share of $0.30 and warrants to get up to 12,000,000 shares of CEL-SCI Corporation’s common stock at a purchase price of $0.40.

Has started delivery bupropion hydrochloride extended discharge tablets.

Caraco Pharmaceutical Laboratories begins marketing bupropion hydrochloride extended discharge tablets Caraco Pharmaceutical Laboratories, Ltd. has started delivery bupropion hydrochloride extended discharge tablets. This product was recently approved by the US Food and Medication Administration for Sunlight Pharma’s Abbreviated New Drug Program . These strengths of generic bupropion hydrochloride extended launch tablets have annual sales of around $300 million in the US. Bupropion Hydrochloride Extended Discharge tablets are indicated for the treating major depressive disorder.